Hikma Pharmaceuticals Regulatory News (HIK)

Michael Ashton Appointment to PuriCore plc

London, 1 February 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) makes this announcement in accordance with Listing Rule LR 9.6.14, which requires Hikma to notify the market when directors of Hikma become directors of other publicly traded companies.

Mr. Michael Ashton, an independent non-executive director of Hikma, has been appointed as an independent non-executive director of PuriCore plc (LSE: PURI) with effect from 1 February 2012.

"PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation." Source: PuriCore plc

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles, Company Secretary +44 (0)20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).